CELG:NSD-Celgene Corporation (USD)

COMMON STOCK | Drug Manufacturers—General | NSD

Last Closing Price

USD 108.24

Change

0.00 (0.00)%

Market Cap

USD 77.04B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. The company also has strategic collaboration with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey. As of November 20, 2019, Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

N/A

USD136.80B 55.38 19.12
AMGN Amgen Inc

N/A

USD130.88B 18.13 12.40
SNY Sanofi

N/A

USD128.16B 26.36 7.63
GILD Gilead Sciences, Inc

N/A

USD75.25B 59.61 19.40
BIIB Biogen Inc

N/A

USD37.51B 8.02 5.83
GRFS Grifols, S.A

N/A

USD17.27B 31.18 17.12
HZNP Horizon Therapeutics Public Li..

N/A

USD15.57B 19.53 26.60
GWPH GW Pharmaceuticals plc

N/A

USD3.86B 91.14 84.16

ETFs Containing CELG

Symbol Name Weight Mer Price(Change) Market Cap
OSXC:XETRA Ossiam Risk Weighted Enha.. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -1.11% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.11% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.95% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.95% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.89% N/A N/A N/A N/A
Risk Adjusted Return 11.85% N/A N/A N/A N/A
Market Capitalization 77.04B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.33 N/A N/A N/A N/A
Price/Book Ratio 6.37 N/A N/A N/A N/A
Price / Cash Flow Ratio 14.90 N/A N/A N/A N/A
EV/EBITDA 10.62 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 69.39% N/A N/A N/A N/A
Return on Invested Capital 13.89% N/A N/A N/A N/A
Return on Assets 13.69% N/A N/A N/A N/A
Debt to Equity Ratio 320.87% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.45 N/A N/A N/A N/A
Short Percent 1.85% N/A N/A N/A N/A
Beta 1.41 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike